A review of Skye’s current clinical activity and near-term path to Phase 2a data.
Discusses input from obesity physicians that frames the distinct opportunity for a non-GLP1 obesity therapeutic with the target product profile of a peripherally-restricted CB1 inhibitor such as nimacimab.
Hosted by Evercore healthcare equity research analysts, Skye executives join with notable obesity physicians to discuss the CB1 pathway, nimacimab’s peripheral CB1 blockade, and the broader non-incretin toolkit supporting obesity care beyond the limits of the GLP-1 era.
Skye’s poster presentation at the American Diabetes Association medical conference highlights nimacimab’s ability to achieve weight reduction and deliver comprehensive metabolic improvements including enhanced body composition, restoration of metabolic homeostasis, and improved hormonal profiles.
Presentation at this notable obesity-related medical conference reviewed nimacimab’s differentiated characteristics, reiterated meaningful weight loss data from a pre-clinical diet-induced obesity model, and introduced new biomarker data showing important reductions in obesity-induced inflammation and liver steatosis.
At ECO 2025, Skye presented its poster: “Demonstrating the sufficiency of peripheral CB1 inhibition to promote weight loss using clinical pharmacokinetic and pharmacodynamic models”
As part of the 2025 proxy package, this letter reviews what Skye has accomplished, why CB1 matters, and how we intend to move forward.
Skye CEO Punit Dhillon and Clinical Advisory Board Member Dr. Beverly Tchang, MD, chat about the SXSW forum and weight loss in anticipation of the panel they participate in the following day, “Weighing in on Weight Loss.”
On this South by Southwest conference panel, Punit Dhillon and Clinical Advisory Board Member Dr. Beverly Tchang, MD participate in a discussion about the need for improved sustainable weight loss outcomes, emerging scientific advancements, combination therapies, and the possibilities of CB1 inhibition.
CEO Punit Dhillon discusses Skye’s accomplishments in 2024 and the execution plans for 2025, in particular announcing data from its Phase 2 study of nimacimab for weight loss.